Efficacy of Lenses in Abolishing Photoparoxysmal Responses
NCT ID: NCT04076410
Last Updated: 2024-06-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
NA
Total Enrollment
28 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-02-20
Study Completion Date
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background. Blue lenses that filter out red light have been proposed as a new therapeutic alternative for patients with PSE, such as the lens Zeiss Clarlet Z1. This lens only allows a small overall quantity of visible light, and particularly a minimum percentage of red light, to pass through. However, these characteristics entail two main pitfalls: reduced applicability in high- latitude regions and lack of transmission for the red and yellow colors. The latter would mainly expose patients to the other colors that compose the visible light, and particularly to the blue visible light. This exposure might be damaging for their eyes in the long term, as it has been reported in some studies.
Aim. To determine whether four new lenses with different spectral characteristics are not inferior in efficacy to Z1 to reduce the PPRs in patients with PSE.
Participants. Patients between 5-18 years with suspected or confirmed PSE, referred to the Neurophysiology Service at Birmingham Children's Hospital (BCH) for an EEG with IPS/pattern stimulation.
Objectives \& Outcomes:
1.A) Primary Objective: To evaluate the reduction/suppression produced by four new lenses in the PPRs shown by patients with PSE during an EEG with IPS/pattern stimulation, and compare it with the reduction provoked by the Z1 lens in the same individuals.
1. B) Primary Outcome: reduction/suppression in both the PPR and the standardized photoparoxysmal response range (SPR) for IPS and pattern stimulation.
2. A) Secondary Objectives:
* To obtain feedback from the patients who acquire a pair of our lenses regarding tolerability, overall adherence to treatment and improvement in the quality of life.
* Comparison of the reduction/suppression in the PPRs between our lenses and the Z1 lens in those retrospective patients with PSE seen between 2008-2017 at the Aston Brain Center.
2.B) Secondary Outcomes:
* Mean score obtained in adherence to treatment, tolerability, reduction in seizure frequency and autonomy according to the patient/parents or carers satisfaction questionnaires.
* Reduction/suppression in both the PPR and the standardized photoparoxysmal response range (SPR) for IPS and pattern stimulation in those patients recruited at the Aston Brain Center.
Aim. To determine whether four new lenses with different spectral characteristics are not inferior in efficacy to Z1 to reduce the PPRs in patients with PSE.
Participants. Patients between 5-18 years with suspected or confirmed PSE, referred to the Neurophysiology Service at Birmingham Children's Hospital (BCH) for an EEG with IPS/pattern stimulation.
Objectives \& Outcomes:
1.A) Primary Objective: To evaluate the reduction/suppression produced by four new lenses in the PPRs shown by patients with PSE during an EEG with IPS/pattern stimulation, and compare it with the reduction provoked by the Z1 lens in the same individuals.
1. B) Primary Outcome: reduction/suppression in both the PPR and the standardized photoparoxysmal response range (SPR) for IPS and pattern stimulation.
2. A) Secondary Objectives:
* To obtain feedback from the patients who acquire a pair of our lenses regarding tolerability, overall adherence to treatment and improvement in the quality of life.
* Comparison of the reduction/suppression in the PPRs between our lenses and the Z1 lens in those retrospective patients with PSE seen between 2008-2017 at the Aston Brain Center.
2.B) Secondary Outcomes:
* Mean score obtained in adherence to treatment, tolerability, reduction in seizure frequency and autonomy according to the patient/parents or carers satisfaction questionnaires.
* Reduction/suppression in both the PPR and the standardized photoparoxysmal response range (SPR) for IPS and pattern stimulation in those patients recruited at the Aston Brain Center.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Light-Blocking Lenses on Pediatric Hyperopia
NCT07142915
Hyperopia
NOT_YET_RECRUITING
NA
Light Diffraction Glasses in Preventing and Controlling Myopia in Adolescents
NCT06927414
Myopia Progressing
ACTIVE_NOT_RECRUITING
NA
3D Designed Defocus Lenses on Myopia Control in Children and Adolescents
NCT07284147
Myopia Progressing
ENROLLING_BY_INVITATION
NA
Enhancement of Emmetropization in Hyperopic Infants
NCT00574717
Hyperopia
Hypermetropia
Farsightedness
TERMINATED
PHASE1/PHASE2
Optimization of a Photoretinoscopy Method for Determining the Objective Refraction of Children With a Smartphone/add-on Device in India
NCT06524115
Ametropia
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. BACKGROUND
Photosensitive epilepsy (PSE) is the most common of reflex epilepsies and represents approximately 10% of all new cases of epilepsy in the age range 7-19 years (Harding \& Jeavons, 1994). Photosensitivity is the nuclear feature of PSE, in which seizures are provoked by light stimuli or visual patterns, such as lines, gratings or checkerboards (Yalçin, Kaymaz, \& Forta, 2000)(Fisher, Harding, Erba, Barkley, \& Wilkins, 2005). Therefore, usual external triggers of seizures in the daily life of patients with PSE are sunlight and screens, like televisions (TVs), video games and computer displays. Photic/pattern sensitivity can be detected on the electroencephalogram (EEG) by the presence of a specific abnormality, called the 'photoparoxysmal response' (PPR), which is usually evoked by intermittent photic stimulation (IPS) or pattern stimulation, respectively (Quirk et al., 1995). Red color (wavelength around 600-700nm) has been proposed to be the most provocative stimulus among the primary colors to trigger photosensitivity/pattern-sensitivity in these patients (Fisher et al., 2005)(Guerrini \& Genton, 2004).
There are certain preventive measures to avoid triggering external stimuli which are particularly useful in PSE patients, but pharmacological treatment is required when seizures are not controlled by preventive measures or when photic or pattern-induced seizures coexist with spontaneous seizures. However, adverse effects of antiepileptic drugs (AEDs) and the relapse percentage after medication withdrawal, which may be nearly 50% (Verrotti et al., 2014), drove investigators to seek other therapeutic alternatives, such as the use of blue lenses that filter out red light. To date, the most extensively investigated lens has been Zeiss Clarlet Z1, which abolished PPRs in 75.9% of 610 patients (Giuseppe Capovilla et al., 2006). This effect was accounted for by the spectroscopic profile of Z1, that shows the minimal transmittance for the spectrum of red color (600-700 nm) (G Capovilla et al., 1999) and a luminous transmittance for the visible spectrum (τν) around 7%.
However, Z1 transmittance characteristics have two main limitations for its use in everyday life: 1) it is a very dark lens and not practical in high-latitude regions, where the number of sunlight hours is reduced; 2) its lack of transmission in the red and yellow parts of the spectrum determines that people using Z1 are almost completely exposed to blue visible light, which has been associated with the appearance of ophthalmological diseases in the long term, such as age-related macular degeneration (AMD) ("blue-light hazard" phenomenon) (Mainster, 2006).
2. RATIONALE
In light of these limitations, we hypothesized that a new type of lenses created by improving some spectral characteristics of Z1 could also be helpful for patients with PSE. This is the reason why we have designed four new lenses at the Aston Brain Center (ABC, Aston University) in collaboration with the Aston University Vision Sciences Department. These new lenses were firstly tested in those patients with PSE referred to the ABC between 2008-2017, when this center was the referral site in West Midlands to perform an EEG with photic/pattern stimulation.
To date, no lens has demonstrated similar efficacy to Z1 with improved transmittance characteristics. Our new lenses may become an alternative or adjuvant therapy for paediatric and adult patients with PSE, leading to a reduction in the necessary dose of medication, with consequently less probability of adverse effects and an overall improvement in the quality of life.
3. AIM AND OBJECTIVES
The aim of our study is to demonstrate that our lenses are not inferior in efficacy to reduce the PPRs in comparison with Z1 in a sample of children and adolescents with PSE.
1. The primary objective of this study is to investigate the efficacy of these four lenses in suppressing the PPRs evoked by IPS and/or pattern stimulation in a sample of pediatric patients with PSE recruited at the Birmingham Women's and Children's NHS Foundation Trust (BWCH), and compare their results with those obtained with Z1 in the same patient.
2. Our secondary objectives are:
* To collect the retrospective information (clinical and EEG data) of those PSE patients who were seen between 2008 and 2017 at the ABC, where the lenses were firstly tested before moving the equipment to the BWCH.
* To obtain feedback from the patients who finally acquire a pair of our lenses in relation to the overall adherence to treatment, tolerability and improvement in the quality of life. To achieve this objective, we will send a patient satisfaction questionnaire (PSQ) to these patients approximately 6 months after purchasing the lenses.
4\. DESIGN
This is a single-arm clinical trial. We will carry out two types of study: a prospective (forward) study recruiting patients at BWCH and also a retrospective (backwards) study collecting those patients seen at the ABC between 2008 and 2017. In both studies, data analysis will take place at Aston University after being pseudonymized.
5\. METHODS
5.1. Recruitment
Prospective study (BWCH, Aston University):
Patients (either males or females) from 5 to 18 years with suspected or confirmed diagnosis of generalised epilepsy with photosensitivity or photosensitive epilepsy (PSE) who are referred to the Neurophysiology Service at BCH for an EEG with IPS/pattern stimulation to confirm the diagnosis or check evolution, whether they are taking AEDs or not. Participants will be able to maintain concentration during the procedure, follow simple commands given by the NHS PI and have the capacity to assent (under 16 years) or consent (16-18 years) to participate after checking that they have understood the purpose of the study.
Retrospective study (Aston University):
•Selection criteria followed in the retrospective study conducted at the ABC were the same, except for the age criterion, since adult patients were also seen at the ABC.
5.2. Trial Procedures
Prospective study (BWCH, Aston University):
* On the first visit to the BWCH, a standardised procedure for EEG with IPS (Kasteleijn-Nolst Trenité et al., 2012) will be performed, followed by stimulation with visual patterns (stationary vertical grids at different spatial frequencies on a screen). If PPRs are shown in response to IPS/pattern stimulation, lenses will be tested to evaluate the relative reduction produced by our lenses \& Z1 on the PPRs evoked by IPS/pattern testing. This reduction will be determined by the change in both the type of PPR and the standardized photoparoxysmal response range (SPR).
* If our lenses are effective and patients/families decide to acquire one of them, they will be asked to fill in a Likert-scale PSQ approximately 6 months after purchasing the lenses. This information will provide us with some feedback on the overall adherence to treatment, tolerability and improvement in the quality of life.
5.2.2) Retrospective study (Aston University): it will consist in the same procedures as the prospective study, but in this case the PSQ was not sent to patients/families.
6\. DATA ANALYSIS
A minimum sample size of 76 patients was obtained based upon data collected from a previous pilot study, taking into consideration a power value of 80%, an alpha value of 5% and a non-inferiority margin of 0.03.
For each patient, we will compare the reduction/suppression on both the PPR and the SPR between the different lenses (α=0.05). PSQ results will be expressed by the percentages of patients/parents who marked a particular response in these multiple-choice questionnaires.
Missed data (patients who finally drop out of the study) will not be considered for analysis purposes.
7\. ETHICAL CONSIDERATIONS
All procedures conducted will comply with the Declaration of Helsinki as revised in 2013, the Data Protection Act 1998 and Local Information Governance protocols. Consent will be sought from parents/legal guardians and patients over 15 years, as well as assent in the case of younger patients.
Only pseudonymized raw data will be available for sharing outside of the department as the analysis is to be performed by the PI-based at the sponsor site (Aston University). Data storage will be in keeping with the Trust Information Governance policies.
Photosensitive epilepsy (PSE) is the most common of reflex epilepsies and represents approximately 10% of all new cases of epilepsy in the age range 7-19 years (Harding \& Jeavons, 1994). Photosensitivity is the nuclear feature of PSE, in which seizures are provoked by light stimuli or visual patterns, such as lines, gratings or checkerboards (Yalçin, Kaymaz, \& Forta, 2000)(Fisher, Harding, Erba, Barkley, \& Wilkins, 2005). Therefore, usual external triggers of seizures in the daily life of patients with PSE are sunlight and screens, like televisions (TVs), video games and computer displays. Photic/pattern sensitivity can be detected on the electroencephalogram (EEG) by the presence of a specific abnormality, called the 'photoparoxysmal response' (PPR), which is usually evoked by intermittent photic stimulation (IPS) or pattern stimulation, respectively (Quirk et al., 1995). Red color (wavelength around 600-700nm) has been proposed to be the most provocative stimulus among the primary colors to trigger photosensitivity/pattern-sensitivity in these patients (Fisher et al., 2005)(Guerrini \& Genton, 2004).
There are certain preventive measures to avoid triggering external stimuli which are particularly useful in PSE patients, but pharmacological treatment is required when seizures are not controlled by preventive measures or when photic or pattern-induced seizures coexist with spontaneous seizures. However, adverse effects of antiepileptic drugs (AEDs) and the relapse percentage after medication withdrawal, which may be nearly 50% (Verrotti et al., 2014), drove investigators to seek other therapeutic alternatives, such as the use of blue lenses that filter out red light. To date, the most extensively investigated lens has been Zeiss Clarlet Z1, which abolished PPRs in 75.9% of 610 patients (Giuseppe Capovilla et al., 2006). This effect was accounted for by the spectroscopic profile of Z1, that shows the minimal transmittance for the spectrum of red color (600-700 nm) (G Capovilla et al., 1999) and a luminous transmittance for the visible spectrum (τν) around 7%.
However, Z1 transmittance characteristics have two main limitations for its use in everyday life: 1) it is a very dark lens and not practical in high-latitude regions, where the number of sunlight hours is reduced; 2) its lack of transmission in the red and yellow parts of the spectrum determines that people using Z1 are almost completely exposed to blue visible light, which has been associated with the appearance of ophthalmological diseases in the long term, such as age-related macular degeneration (AMD) ("blue-light hazard" phenomenon) (Mainster, 2006).
2. RATIONALE
In light of these limitations, we hypothesized that a new type of lenses created by improving some spectral characteristics of Z1 could also be helpful for patients with PSE. This is the reason why we have designed four new lenses at the Aston Brain Center (ABC, Aston University) in collaboration with the Aston University Vision Sciences Department. These new lenses were firstly tested in those patients with PSE referred to the ABC between 2008-2017, when this center was the referral site in West Midlands to perform an EEG with photic/pattern stimulation.
To date, no lens has demonstrated similar efficacy to Z1 with improved transmittance characteristics. Our new lenses may become an alternative or adjuvant therapy for paediatric and adult patients with PSE, leading to a reduction in the necessary dose of medication, with consequently less probability of adverse effects and an overall improvement in the quality of life.
3. AIM AND OBJECTIVES
The aim of our study is to demonstrate that our lenses are not inferior in efficacy to reduce the PPRs in comparison with Z1 in a sample of children and adolescents with PSE.
1. The primary objective of this study is to investigate the efficacy of these four lenses in suppressing the PPRs evoked by IPS and/or pattern stimulation in a sample of pediatric patients with PSE recruited at the Birmingham Women's and Children's NHS Foundation Trust (BWCH), and compare their results with those obtained with Z1 in the same patient.
2. Our secondary objectives are:
* To collect the retrospective information (clinical and EEG data) of those PSE patients who were seen between 2008 and 2017 at the ABC, where the lenses were firstly tested before moving the equipment to the BWCH.
* To obtain feedback from the patients who finally acquire a pair of our lenses in relation to the overall adherence to treatment, tolerability and improvement in the quality of life. To achieve this objective, we will send a patient satisfaction questionnaire (PSQ) to these patients approximately 6 months after purchasing the lenses.
4\. DESIGN
This is a single-arm clinical trial. We will carry out two types of study: a prospective (forward) study recruiting patients at BWCH and also a retrospective (backwards) study collecting those patients seen at the ABC between 2008 and 2017. In both studies, data analysis will take place at Aston University after being pseudonymized.
5\. METHODS
5.1. Recruitment
Prospective study (BWCH, Aston University):
Patients (either males or females) from 5 to 18 years with suspected or confirmed diagnosis of generalised epilepsy with photosensitivity or photosensitive epilepsy (PSE) who are referred to the Neurophysiology Service at BCH for an EEG with IPS/pattern stimulation to confirm the diagnosis or check evolution, whether they are taking AEDs or not. Participants will be able to maintain concentration during the procedure, follow simple commands given by the NHS PI and have the capacity to assent (under 16 years) or consent (16-18 years) to participate after checking that they have understood the purpose of the study.
Retrospective study (Aston University):
•Selection criteria followed in the retrospective study conducted at the ABC were the same, except for the age criterion, since adult patients were also seen at the ABC.
5.2. Trial Procedures
Prospective study (BWCH, Aston University):
* On the first visit to the BWCH, a standardised procedure for EEG with IPS (Kasteleijn-Nolst Trenité et al., 2012) will be performed, followed by stimulation with visual patterns (stationary vertical grids at different spatial frequencies on a screen). If PPRs are shown in response to IPS/pattern stimulation, lenses will be tested to evaluate the relative reduction produced by our lenses \& Z1 on the PPRs evoked by IPS/pattern testing. This reduction will be determined by the change in both the type of PPR and the standardized photoparoxysmal response range (SPR).
* If our lenses are effective and patients/families decide to acquire one of them, they will be asked to fill in a Likert-scale PSQ approximately 6 months after purchasing the lenses. This information will provide us with some feedback on the overall adherence to treatment, tolerability and improvement in the quality of life.
5.2.2) Retrospective study (Aston University): it will consist in the same procedures as the prospective study, but in this case the PSQ was not sent to patients/families.
6\. DATA ANALYSIS
A minimum sample size of 76 patients was obtained based upon data collected from a previous pilot study, taking into consideration a power value of 80%, an alpha value of 5% and a non-inferiority margin of 0.03.
For each patient, we will compare the reduction/suppression on both the PPR and the SPR between the different lenses (α=0.05). PSQ results will be expressed by the percentages of patients/parents who marked a particular response in these multiple-choice questionnaires.
Missed data (patients who finally drop out of the study) will not be considered for analysis purposes.
7\. ETHICAL CONSIDERATIONS
All procedures conducted will comply with the Declaration of Helsinki as revised in 2013, the Data Protection Act 1998 and Local Information Governance protocols. Consent will be sought from parents/legal guardians and patients over 15 years, as well as assent in the case of younger patients.
Only pseudonymized raw data will be available for sharing outside of the department as the analysis is to be performed by the PI-based at the sponsor site (Aston University). Data storage will be in keeping with the Trust Information Governance policies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Reflex Epilepsy, Photosensitive
Eyeglasses
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Participants will be recruited among those patients (both males and females) from 5 to 18 years with suspected or confirmed diagnosis of generalised epilepsy with photosensitivity or photosensitive epilepsy (PSE) who comply with the established inclusion criteria.
No control patients will be required, since each patient will be tested with the different lenses in a specific order and will be, in turn, his/her own control. No randomisation will be carried out in our study.
No control patients will be required, since each patient will be tested with the different lenses in a specific order and will be, in turn, his/her own control. No randomisation will be carried out in our study.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
5 Lenses
The five lenses will be tested in each patient following always the same specific order, with the most protective lenses tested first (Z1).
Z1F133 (Zeiss Clarlet Z1) is a CE marked device manufactured by Carl Zeiss Vision International GmBH (Aalen, Germany).
Our lenses are CE marked devices manufactured by Cerium Optical Products (Kent, UK).
Group Type
EXPERIMENTAL
Z1 lens
Intervention Type
DEVICE
CE marked device
Experimental Lens 1
Intervention Type
DEVICE
CE marked device
Experimental Lens 2
Intervention Type
DEVICE
CE marked device
Experimental Lens 3
Intervention Type
DEVICE
CE marked device
Experimental Lens 4
Intervention Type
DEVICE
CE marked device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Z1 lens
CE marked device
Intervention Type
DEVICE
Experimental Lens 1
CE marked device
Intervention Type
DEVICE
Experimental Lens 2
CE marked device
Intervention Type
DEVICE
Experimental Lens 3
CE marked device
Intervention Type
DEVICE
Experimental Lens 4
CE marked device
Intervention Type
DEVICE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Zeiss F133
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Children and adolescents between 5-18 years with suspected or confirmed diagnosis of photosensitive epilepsy (PSE), whether they are taking antiepileptic medication or not.
2. Capacity to:
* maintain concentration during the procedure
* follow simple commands
* assent (under 16 years) or consent (16-18 years) to participate after understanding the purpose of the study.
2. Capacity to:
* maintain concentration during the procedure
* follow simple commands
* assent (under 16 years) or consent (16-18 years) to participate after understanding the purpose of the study.
Exclusion Criteria
1. Presence of a condition that may compromise the ability to tolerate the procedure and/or the capacity to assent or consent, such as:
* intellectual disability
* attention-deficit/hyperactivity disorder
* autism spectrum disorders
* difficulties to understand verbal/written explanations in English
2. Refusal to participate
3. Generalized seizure during the EEG procedure.
4. Female patients suspected or known to be pregnant.
* intellectual disability
* attention-deficit/hyperactivity disorder
* autism spectrum disorders
* difficulties to understand verbal/written explanations in English
2. Refusal to participate
3. Generalized seizure during the EEG procedure.
4. Female patients suspected or known to be pregnant.
Minimum Eligible Age
5 Years
Maximum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Birmingham Women's and Children's NHS Foundation Trust
OTHER
Sponsor Role
collaborator
Aston University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ana Checa-Ros, MD, PhD
Honorary Research Fellow
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bryony Carr, BSc
Role: PRINCIPAL_INVESTIGATOR
Birmingham Women's and Children's NHS Foundation Trust
Ana Checa-Ros, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Aston University, Birmingham, UK
Sukhvir Wright, MD, PhD
Role: STUDY_CHAIR
Aston University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham Women's and Children's NHS Foundation Trust
Birmingham, West Midlands, United Kingdom
Site Status
Aston University
Birmingham, West Midlands, United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
References
Explore related publications, articles, or registry entries linked to this study.
Capovilla G, Beccaria F, Romeo A, Veggiotti P, Canger R, Paladin F. Effectiveness of a particular blue lens on photoparoxysmal response in photosensitive epileptic patients. Ital J Neurol Sci. 1999 Jun;20(3):161-6. doi: 10.1007/s100720050026.
Reference Type
BACKGROUND
Capovilla G, Gambardella A, Rubboli G, Beccaria F, Montagnini A, Aguglia U, Canevini MP, Casellato S, Granata T, Paladin F, Romeo A, Stranci G, Tinuper P, Veggiotti P, Avanzini G, Tassinari CA. Suppressive efficacy by a commercially available blue lens on PPR in 610 photosensitive epilepsy patients. Epilepsia. 2006 Mar;47(3):529-33. doi: 10.1111/j.1528-1167.2006.00463.x.
Reference Type
BACKGROUND
Fisher RS, Harding G, Erba G, Barkley GL, Wilkins A; Epilepsy Foundation of America Working Group. Photic- and pattern-induced seizures: a review for the Epilepsy Foundation of America Working Group. Epilepsia. 2005 Sep;46(9):1426-41. doi: 10.1111/j.1528-1167.2005.31405.x.
Reference Type
BACKGROUND
Guerrini R, Genton P. Epileptic syndromes and visually induced seizures. Epilepsia. 2004;45 Suppl 1:14-8. doi: 10.1111/j.0013-9580.2004.451011.x.
Reference Type
BACKGROUND
Harding, G., & Jeavons, P. (1994). Photosensitive Epilepsy: Clinics in Developmental Medicine. London, UK: McKeith Press.
Reference Type
BACKGROUND
Kasteleijn-Nolst Trenite D, Rubboli G, Hirsch E, Martins da Silva A, Seri S, Wilkins A, Parra J, Covanis A, Elia M, Capovilla G, Stephani U, Harding G. Methodology of photic stimulation revisited: updated European algorithm for visual stimulation in the EEG laboratory. Epilepsia. 2012 Jan;53(1):16-24. doi: 10.1111/j.1528-1167.2011.03319.x. Epub 2011 Nov 16.
Reference Type
BACKGROUND
Mainster MA. Violet and blue light blocking intraocular lenses: photoprotection versus photoreception. Br J Ophthalmol. 2006 Jun;90(6):784-92. doi: 10.1136/bjo.2005.086553.
Reference Type
BACKGROUND
Quirk JA, Fish DR, Smith SJ, Sander JW, Shorvon SD, Allen PJ. Incidence of photosensitive epilepsy: a prospective national study. Electroencephalogr Clin Neurophysiol. 1995 Oct;95(4):260-7. doi: 10.1016/0013-4694(95)00118-i.
Reference Type
BACKGROUND
Verrotti A, Grosso S, D'Egidio C, Parisi P, Spalice A, Pavone P, Capovilla G, Agostinelli S. Valproate in adolescents with photosensitive epilepsy with generalized tonic-clonic seizures only. Eur J Paediatr Neurol. 2014 Jan;18(1):13-8. doi: 10.1016/j.ejpn.2013.06.006. Epub 2013 Jul 26.
Reference Type
BACKGROUND
Yalcin AD, Kaymaz A, Forta H. Reflex occipital lobe epilepsy. Seizure. 2000 Sep;9(6):436-41. doi: 10.1053/seiz.2000.0424.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
266497
Identifier Type: OTHER
Identifier Source: secondary_id
20/EM/0030
Identifier Type: OTHER
Identifier Source: secondary_id
284-2019-CR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of Peripheral Defocus on Axial Growth in Hyperopes
NCT02686879
COMPLETED
NA
Tolerability of a Novel Spectacle Design With Reduced Peripheral Contrast
NCT03761758
COMPLETED
NA
Peripheral Relative Refractive Power of Orthokeratology Lenses
NCT07294404
COMPLETED
Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine
NCT04923841
RECRUITING
NA
A Study to Evaluate the Safety and Effectiveness of the 217z Laser With Zyoptix for Lasik
NCT00347997
WITHDRAWN
NA
A Randomized Clinical Trial on the Effectiveness of Novel Plano Spectacle Lenses on Myopia Prevention in Pre-myopic Children
NCT06860737
ACTIVE_NOT_RECRUITING
NA
Pilot Study to Assess the Efficacy of Short Exposure to Defocus to Slow the Progression of Myopia in Children
NCT00400140
COMPLETED
NA
Efficacy of Coloured Overlays and Lenses for Reading Difficulty
NCT02680223
COMPLETED
NA
Optimization of a Photoretinoscopy Method for Determining the Objective Refraction of Children
NCT06295536
COMPLETED
NA
Performance of Refractometers With Self-adjusting Lenses Compared to Cycloplegia in Children (REFRALENS)
NCT06668246
ACTIVE_NOT_RECRUITING
Perceptual Learning Treatment for Amblyopia
NCT03788031
COMPLETED
NA
Efficacy and Safety of Eyetronix Flicker Glasses to the Treatment of Anisometropic Amblyopia
NCT02970708
UNKNOWN
NA
Effect of Light-Blocking Lenses on Hyperopic Anisometropic Children
NCT07142928
NOT_YET_RECRUITING
NA
Impact of Color Correcting Lenses on Color Vision Deficiency
NCT05463016
COMPLETED
NA
Peripheral Optics in Myopia and Orthokeratology
NCT00978679
COMPLETED
NA
Red Light Childhood Myopia Proof-of-concept
NCT06771258
NOT_YET_RECRUITING
NA
Topical 0.01% Atropine for the Control of Fast Progressing Myopia
NCT04173780
TERMINATED
PHASE2/PHASE3
Determining the Efficacy of Full-time Occlusion Therapy in Severe Amblyopia at Different Ages
NCT02113709
UNKNOWN
NA
Development of a New Device and Method to Assess the Degree of Myopia and/or Astigmatism in Myopic People
NCT07297810
NOT_YET_RECRUITING
NA
Efficacy of Visual and Perceptual Training on Visual Function for Operative Congenital Ectopia Lentis Children
NCT07096622
NOT_YET_RECRUITING
NA
A Randomized Trial of Base-in Prism Reading Glasses Convergence Insufficiency in Children
NCT00347581
COMPLETED
PHASE3
Control of Myopia Using Novel Spectacle Lens Designs
NCT03623074
ACTIVE_NOT_RECRUITING
NA
Clinical Investigation of a Novel Spectacle Lens on Slowing Down Juvenile Myopia Progression
NCT06850168
RECRUITING
NA